journal article·2026-01-09

mRNA technology for the prevention and treatment of HIV-1 infection

Chuang Liu, Alexey V. Yaremenko, Xiaolong Li, Xinru You, Xiaoyu Zhu, Nuo Liu, Wei Chen, Na Kong, Tian Xie, Gaurav D. Gaiha, Robert Langer, Wei Tao

Nature Reviews Bioengineering· Volume 4· Issue 5
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: RNA Interference and Gene Delivery · HIV Research and Treatment · Virus-based gene therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Bekker, L. G. et al. HIV infection. Nat. Rev. Dis. Primers 9, 42 (2023).10.1038/s41572-023-00452-3 ↗
2. Montagnier, L. Historical essay. A history of HIV discovery. Science 298, 1727–1728 (2002).10.1126/science.1079027 ↗
3. Chen, L. et al. Exosomes derived from HIV-1-infected cells promote growth and progression of cancer via HIV TAR RNA. Nat. Commun. 9, 4585 (2018).10.1038/s41467-018-07006-2 ↗
4. Landovitz, R. J., Scott, H. & Deeks, S. G. Prevention, treatment and cure of HIV infection. Nat. Rev. Microbiol. 21, 657–670 (2023).10.1038/s41579-023-00914-1 ↗
5. Gbadamosi, S. O., Trepka, M. J., Dawit, R., Jebai, R. & Sheehan, D. M. A systematic review and meta-analysis to estimate the time from HIV infection to diagnosis for people with HIV. AIDS Rev. 24, 32–40 (2022).
6. Bartlett, J. A. & Shao, J. F. Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. Lancet Infect. Dis. 9, 637–649 (2009).10.1016/S1473-3099(09)70227-0 ↗
7. Grinsztejn, B. et al. Third-line antiretroviral therapy in low-income and middle-income countries: ACTG A5288, a prospective strategy study. Lancet HIV 6, e588–e600 (2019).10.1016/S2352-3018(19)30146-8 ↗
8. Haynes, B. F. et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat. Rev. Immunol. 23, 142–158 (2023).10.1038/s41577-022-00753-w ↗
9. Sok, D. & Burton, D. R. Recent progress in broadly neutralizing antibodies to HIV. Nat. Immunol. 19, 1179–1188 (2018).10.1038/s41590-018-0235-7 ↗
10. Goo, L., Chohan, V., Nduati, R. & Overbaugh, J. Early development of broadly neutralizing antibodies in HIV-1-infected infants. Nat. Med. 20, 655–658 (2014).10.1038/nm.3565 ↗
11. Escolano, A. et al. Sequential immunization elicits broadly neutralizing anti-HIV-1 antibodies in Ig knockin mice. Cell 166, 1445–1458.e12 (2016).10.1016/j.cell.2016.07.030 ↗
12. Steichen, J. M. et al. Vaccine priming of rare HIV broadly neutralizing antibody precursors in nonhuman primates. Science 384, eadj8321 (2024).10.1126/science.adj8321 ↗
13. Willis, J. R. et al. Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans. Science 389, eadr8382 (2025).10.1126/science.adr8382 ↗
14. Kelsoe, G. & Haynes, B. F. Host controls of HIV broadly neutralizing antibody development. Immunol. Rev. 275, 79–88 (2017).10.1111/imr.12508 ↗
15. Burton, D. R. & Mascola, J. R. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 16, 571–576 (2015).10.1038/ni.3158 ↗
16. Kwong, P. D., Mascola, J. R. & Nabel, G. J. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat. Rev. Immunol. 13, 693–701 (2013).10.1038/nri3516 ↗
17. Barouch, D. H. et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet 392, 232–243 (2018).10.1016/S0140-6736(18)31364-3 ↗
18. Barouch, D. H. et al. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science 349, 320–324 (2015).10.1126/science.aab3886 ↗
19. Gray, G. E. et al. Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults. N. Engl. J. Med. 384, 1089–1100 (2021).10.1056/NEJMoa2031499 ↗
20. Gray, G. E. et al. Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Infect. Dis. 24, 1201–1212 (2024).10.1016/S1473-3099(24)00358-X ↗
21. Kay, M. A. AAV vectors and tumorigenicity. Nat. Biotechnol. 25, 1111–1113 (2007).10.1038/nbt1007-1111 ↗
22. Donsante, A. et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 317, 477 (2007).10.1126/science.1142658 ↗
23. Nguyen, G. N. et al. A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nat. Biotechnol. 39, 47–55 (2021).10.1038/s41587-020-0741-7 ↗
24. Wang, D., Zhang, F. & Gao, G. CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell 181, 136–150 (2020).10.1016/j.cell.2020.03.023 ↗
25. Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines — a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018).10.1038/nrd.2017.243 ↗
26. Mu, Z., Haynes, B. F. & Cain, D. W. HIV mRNA vaccines — progress and future paths. Vaccines 9, 134 (2021).10.3390/vaccines9020134 ↗
27. Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078–1094 (2021).10.1038/s41578-021-00358-0 ↗
28. Chaudhary, N., Weissman, D., Whitehead, K. A., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817–838 (2021).10.1038/s41573-021-00283-5 ↗
29. McGee, J. E. et al. Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency. Nat. Biotechnol. 43, 720–726 (2025).10.1038/s41587-024-02306-z ↗
30. Wu, X. et al. The impact of COVID-19 non-pharmaceutical interventions on HIV care continuum in China: an interrupted time series analysis. Lancet Reg. Health West. Pac. 29, 100569 (2022).
31. Pardi, N. et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J. Exp. Med. 215, 1571–1588 (2018).10.1084/jem.20171450 ↗
32. Huang, X. et al. Nanotechnology-based strategies against SARS-CoV-2 variants. Nat. Nanotechnol. 17, 1027–1037 (2022).10.1038/s41565-022-01174-5 ↗
33. Meulewaeter, S. et al. Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures. J. Control. Rel. 357, 149–160 (2023).10.1016/j.jconrel.2023.03.039 ↗
34. Ju, Y. et al. Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines. Nat. Rev. Immunol. 23, 135–136 (2023).10.1038/s41577-022-00825-x ↗
35. Goel, R. R. et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374, abm0829 (2021).10.1126/science.abm0829 ↗
36. Riddler, S. A. et al. High frequency of chronic urticaria following an investigational HIV-1 BG505 MD39.3 trimer mRNA vaccine in a phase 1, randomized, open-label clinical trial (HVTN 302). Ann. Intern. Med. 178, 963–974 (2025).10.7326/ANNALS-24-02701 ↗
37. Parks, K. R. et al. Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial. Sci. Transl. Med. 17, eady6831 (2025).10.1126/scitranslmed.ady6831 ↗
38. Pardi, N. et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat. Commun. 8, 14630 (2017).10.1038/ncomms14630 ↗
39. Zhang, P. et al. A multiclade env–gagVLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nat. Med. 27, 2234–2245 (2021).10.1038/s41591-021-01574-5 ↗
40. Engelman, A. & Cherepanov, P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat. Rev. Microbiol. 10, 279–290 (2012).10.1038/nrmicro2747 ↗
41. Wyatt, R. & Sodroski, J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280, 1884–1888 (1998).10.1126/science.280.5371.1884 ↗
42. Julien, J.-P. et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342, 1477–1483 (2013).10.1126/science.1245625 ↗
43. Stano, A. et al. Dense array of spikes on HIV-1 virion particles. J. Virol. 91, https://doi.org/10.1128/jvi.00415-17 (2017).10.1128/jvi.00415-17 ↗
44. Mansky, L. M. The mutation rate of human immunodeficiency virus type 1 is influenced by the vpr gene. Virology 222, 391–400 (1996).10.1006/viro.1996.0436 ↗
45. Leitner, T. & Albert, J. The molecular clock of HIV-1 unveiled through analysis of a known transmission history. Proc. Natl Acad. Sci. USA 96, 10752–10757 (1999).10.1073/pnas.96.19.10752 ↗
46. Hemelaar, J. The origin and diversity of the HIV-1 pandemic. Trends Mol. Med. 18, 182–192 (2012).10.1016/j.molmed.2011.12.001 ↗
47. McLaren, P. J. & Carrington, M. The impact of host genetic variation on infection with HIV-1. Nat. Immunol. 16, 577–583 (2015).10.1038/ni.3147 ↗
48. Simon, V., Bloch, N. & Landau, N. R. Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. Nat. Immunol. 16, 546–553 (2015).10.1038/ni.3156 ↗
49. Burton, D. R. & Hangartner, L. Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu. Rev. Immunol. 34, 635–659 (2016).10.1146/annurev-immunol-041015-055515 ↗
50. Haynes, B. F., Burton, D. R. & Mascola, J. R. Multiple roles for HIV broadly neutralizing antibodies. Sci. Transl. Med. 11, eaaz2686 (2019).10.1126/scitranslmed.aaz2686 ↗
51. Liu, M. et al. Polyreactivity and autoreactivity among HIV-1 antibodies. J. Virol. 89, 784–798 (2015).10.1128/JVI.02378-14 ↗
52. Yang, G. et al. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J. Exp. Med. 210, 241–256 (2013).10.1084/jem.20121977 ↗
53. Steichen, J. M. et al. HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies. Immunity 45, 483–496 (2016).10.1016/j.immuni.2016.08.016 ↗
54. Jardine, J. G. et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 351, 1458–1463 (2016).10.1126/science.aad9195 ↗
55. Huang, D. et al. B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models. Proc. Natl Acad. Sci. USA 117, 22920–22931 (2020).10.1073/pnas.2004489117 ↗
56. Bruel, T. et al. Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat. Commun. 7, 10844 (2016).10.1038/ncomms10844 ↗
57. Liu, Y., Cao, W., Sun, M. & Li, T. Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities. Emerg. Microbes Infect. 9, 194–206 (2020).10.1080/22221751.2020.1713707 ↗
58. Chun, T.-W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183–188 (1997).10.1038/387183a0 ↗
59. Maldarelli, F. et al. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345, 179–183 (2014).10.1126/science.1254194 ↗
60. Douek, D. C. et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417, 95–98 (2002).10.1038/417095a ↗
61. Goulder, P. J. R. & Watkins, D. I. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat. Rev. Immunol. 8, 619–630 (2008).10.1038/nri2357 ↗
62. Desrosiers, R. C. Strategies used by human immunodeficiency virus that allow persistent viral replication. Nat. Med. 5, 723–725 (1999).10.1038/10439 ↗
63. Walker, B. D. & Yu, X. G. Unravelling the mechanisms of durable control of HIV-1. Nat. Rev. Immunol. 13, 487–498 (2013).10.1038/nri3478 ↗
64. Bailon, L. et al. Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial. Nat. Med. 28, 2611–2621 (2022).10.1038/s41591-022-02060-2 ↗
65. Gaiha, G. D. et al. Structural topology defines protective CD8+ T cell epitopes in the HIV proteome. Science 364, 480–484 (2019).10.1126/science.aav5095 ↗
66. Kopycinski, J. et al. Therapeutic vaccination following early antiretroviral therapy elicits highly functional T cell responses against conserved HIV-1 regions. Sci. Rep. 13, 17155 (2023).10.1038/s41598-023-42888-3 ↗
67. Lee, J. H. et al. Long-primed germinal centres with enduring affinity maturation and clonal migration. Nature 609, 998–1004 (2022).10.1038/s41586-022-05216-9 ↗
68. Wang, X. et al. mRNA-LNP prime boost evolves precursors toward VRC01-like broadly neutralizing antibodies in preclinical humanized mouse models. Sci. Immunol. 9, eadn0622 (2024).10.1126/sciimmunol.adn0622 ↗
69. Xie, Z. et al. mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies. Science 384, eadk0582 (2024).10.1126/science.adk0582 ↗
70. Wood, J. M. & Robertson, J. S. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat. Rev. Microbiol. 2, 842–847 (2004).10.1038/nrmicro979 ↗
71. Lauring, A. S., Jones, J. O. & Andino, R. Rationalizing the development of live attenuated virus vaccines. Nat. Biotechnol. 28, 573–579 (2010).10.1038/nbt.1635 ↗
72. McMichael, A. J. & Hanke, T. HIV vaccines 1983–2003. Nat. Med. 9, 874–880 (2003).10.1038/nm0703-874 ↗
73. Burton, D. R. Advancing an HIV vaccine; advancing vaccinology. Nat. Rev. Immunol. 19, 77–78 (2019).10.1038/s41577-018-0103-6 ↗
74. Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275–1286 (2012).10.1056/NEJMoa1113425 ↗
75. Hammer, S. M. et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 369, 2083–2092 (2013).10.1056/NEJMoa1310566 ↗
76. Gebre, M. S. et al. Novel approaches for vaccine development. Cell 184, 1589–1603 (2021).10.1016/j.cell.2021.02.030 ↗
77. Travieso, T., Li, J., Mahesh, S., Mello, J. & Blasi, M. The use of viral vectors in vaccine development. npj Vaccines 7, 75 (2022).10.1038/s41541-022-00503-y ↗
78. Picker, L. J., Lifson, J. D., Gale, M. Jr, Hansen, S. G. & Fruh, K. Programming cytomegalovirus as an HIV vaccine. Trends Immunol. 44, 287–304 (2023).10.1016/j.it.2023.02.001 ↗
79. Verweij, M. C. et al. Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacy. Science 372, eabe9233 (2021).10.1126/science.abe9233 ↗
80. Borducchi, E. N. et al. Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. Nature 540, 284–287 (2016).10.1038/nature20583 ↗
81. Barouch, D. H. & Deeks, S. G. Immunologic strategies for HIV-1 remission and eradication. Science 345, 169–174 (2014).10.1126/science.1255512 ↗
82. Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209–2220 (2009).10.1056/NEJMoa0908492 ↗
83. Buchbinder, S. P. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881–1893 (2008).10.1016/S0140-6736(08)61591-3 ↗
84. McMichael, A. J., Borrow, P., Tomaras, G. D., Goonetilleke, N. & Haynes, B. F. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 10, 11–23 (2010).10.1038/nri2674 ↗
85. Barouch, D. H. Challenges in the development of an HIV-1 vaccine. Nature 455, 613–619 (2008).10.1038/nature07352 ↗
86. Bournazos, S., Gazumyan, A., Seaman, M. S., Nussenzweig, M. C. & Ravetch, J. V. Bispecific anti-HIV-1 antibodies with enhanced breadth and potency. Cell 165, 1609–1620 (2016).10.1016/j.cell.2016.04.050 ↗
87. Saunders, K. O. et al. Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian/human immunodeficiency virus infection. J. Virol. 89, 5895–5903 (2015).10.1128/JVI.00210-15 ↗
88. Pegu, A. et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci. Transl. Med. 6, 243ra288 (2014).10.1126/scitranslmed.3008992 ↗
89. Shingai, M. et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 211, 2061–2074 (2014).10.1084/jem.20132494 ↗
90. Martinez-Navio, J. M. et al. Adeno-associated virus delivery of anti-HIV monoclonal antibodies can drive long-term virologic suppression. Immunity 50, 567–575.e5 (2019).10.1016/j.immuni.2019.02.005 ↗
91. Gardner, M. R. Promise and progress of an HIV-1 cure by adeno-associated virus vector delivery of anti-HIV-1 biologics. Front. Cell Infect. Microbiol. 10, 176 (2020).10.3389/fcimb.2020.00176 ↗
92. Priddy, F. H. et al. Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. Lancet HIV 6, e230–e239 (2019).10.1016/S2352-3018(19)30003-7 ↗
93. Casazza, J. P. et al. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nat. Med. 28, 1022–1030 (2022).10.1038/s41591-022-01762-x ↗
94. Nahmad, A. D. et al. In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice. Nat. Biotechnol. 40, 1241–1249 (2022).10.1038/s41587-022-01328-9 ↗
95. Liu, S. et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR–Cas gene editing. Nat. Mater. 20, 701–710 (2021).10.1038/s41563-020-00886-0 ↗
96. Patel, S. et al. Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat. Commun. 11, 983 (2020).10.1038/s41467-020-14527-2 ↗
97. Langer, R. & Folkman, J. Polymers for the sustained release of proteins and other macromolecules. Nature 263, 797–800 (1976).10.1038/263797a0 ↗
98. Dimitriadis, G. J. Translation of rabbit globin mRNA introduced by liposomes into mouse lymphocytes. Nature 274, 923–924 (1978).10.1038/274923a0 ↗
99. Ostro, M. J., Giacomoni, D., Lavelle, D., Paxton, W. & Dray, S. Evidence for translation of rabbit globin mRNA after liposome-mediated insertion into a human cell line. Nature 274, 921–923 (1978).10.1038/274921a0 ↗
100. Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543, 248–251 (2017).10.1038/nature21428 ↗